Here's a very brief update from Beech Tree Labs on TML: Phase I/IIb trials, which were announced in September, 2010, are still ongoing. They are awaiting the enrollment and testing of a few more subjects. No date is set for release of any data. TML has shown greater efficacy than acyclovir. It has an effect on herpes in the dorsal root ganglia.* Dosage would be one drop sublingually, several times a day. It can be used for suppression of outbreaks as well (presumably at a different dosage). It works by inhibiting the reassembly of components of new virion particles. * I'm trying to get a follow-up on this, but it this likely means that it helps maintain latency, as opposed to actually depleting the latent virus. Either way, it sounds interesting, and it'll be nice to see some data when they're done.